CoChat

The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.

Metformin and Inflammation: Its Potential Beyond Glucose-lowering Effect

Saisho, Yoshifumi · 2015 · Endocrine, Metabolic & Immune Disorders-Drug Targets

Abstract

Metformin is an oral hypoglycemic agent which is most widely used as first-line therapy for type 2 diabetes. Metformin improves hyperglycemia by suppressing hepatic glucose production and increasing glucose uptake in muscle. Metformin also has been shown to reduce cardiovascular events in randomized controlled trials; however, the underlying mechanism remains to be established. Recent preclinical and clinical studies have suggested that metformin not only improves chronic inflammation through the improvement of metabolic parameters such as hyperglycemia, insulin resistance and atherogenic dyslipidemia, but also has a direct anti-inflammatory action. Studies have suggested that metformin suppresses inflammatory response by inhibition of nuclear factor κB (NFκB) via AMP-activated protein kinase (AMPK)-dependent and independent pathways. This review summarizes the basic and clinical evidence of the anti-inflammatory action of metformin and discusses its clinical implication.

Overview

Integrity signals

Registry

Crossref · 10.2174/1871530315666150316124019

Cites

92 of 92 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

2 retracted

Show all 92 references

Cited by

See all 453

Metadata

Authors
Saisho, Y.
Affiliations
Keio University (JP)
Corresponding author
Saisho, Yoshifumi
Venue
Endocrine, Metabolic & Immune Disorders-Drug Targets
Published
2015-08-27
Volume
15
Issue
3
Pages
196-205
ISSN
1871-5303 (ISSN-L)
OpenAlex
W185214937
Cited by
450
References
92
Citations by year
2026: 16 · 2025: 31 · 2024: 41 · 2023: 52 · 2022: 56 · 2021: 69 · 2020: 56 · 2019: 43 · 2018: 38 · 2017: 30 · 2016: 15 · 2015: 2
FWCI
12.29
Type
journal article
Language
en
Open access
closed
Locations
  • Endocrine Metabolic & Immune Disorders - Drug Targets (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Keywords
metformin, anti-inflammatory activity, chronic inflammation, type 2 diabetes, NF-κB inhibition, AMPK, insulin resistance, atherogenic dyslipidemia, cardiovascular events, hyperglycemia, hepatic glucose production
MeSH terms
Animals, Anti-Inflammatory Agents, Diabetes Mellitus, Type 2, Glucose, Humans, Hyperglycemia, Hypoglycemic Agents, Inflammation, Metformin, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Metformin and Inflammation: Its Potential Beyond Glucose-lowering Effect. https://app.cochat.ai/papers/10.2174/1871530315666150316124019
The paper
Saisho, Y. (2015). Metformin and Inflammation: Its Potential Beyond Glucose-lowering Effect. Endocrine, Metabolic & Immune Disorders-Drug Targets. https://doi.org/10.2174/1871530315666150316124019

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.